SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Xilio Therapeutics Doses First Patient in Phase 1/2 XTX501 Trial

Xilio Therapeutics said the first patient has been dosed in its Phase 1/2 clinical trial of XTX501 in patients with metastatic NSCLC.

XLO

Related stories